



Customized Product

RecurIndex® Qi

Breast Cancer Prognostic Assay

Most patients with breast cancer are reported to be overtreated. RecurIndex® Qi, empowered by PanelChip®, is the only breast cancer recurrence risk assessment test developed based on Asian genomic profiles by Amwise Diagnostic PTE, LTD, for improving the treatment of breast cancer in Asian population.



For Research Use Only

Key Features

SUITABLE FOR ASIAN

Developed based on genes most related to breast cancer recurrence in Asian population

COMPREHENSIVE

Integrating genetic mapping with clinical factors to predict the 5-year risk of recurrence

REASSURING

Assessing both risk of local recurrence and risk of distant metastasis to minimize unnecessary therapies

CLINICAL VALIDATED

10 years of research and development including validation on 1,200 patients in Singapore and Taiwan

Specifications

Properties	Specifications
Input Analyte Type	Nucleic acids (mRNA)
Input Amount	1 µg/rxn
Target(s) of Detection	30+ mRNA Biomarkers
LRR* Risk Assessment in 5 yrs	Probability: Low risk: < 8%; High Risk: 40%
DR** Risk Assessment in 5 yrs	Probability: Low risk: < 4%; High Risk: 30%
Total Operation Time (from input analyte)	130 min cDNA Synthesis: 30 min Reaction & Analysis: 100 min
Compatible Instrument	NextAmp™ Analysis System (Q Station™ 1000 with PanelChip®)
Specimen Type(s)	FFPE

*LRR: Local regional recurrence

**DR: Distant metastasis

Ordering Information

Reference No.	Product Name	Package Size
RIQ-R-24	RecurIndex® Qi Reagents, BOX 1 of 2	24 Assays
RIQ-C-24	RecurIndex® Qi PanelChip®, BOX 2 of 2	24 Assays

For more information, please contact: info@quarkbiosciences.com